Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to a GABA A receptor subunit epsilon-related protein, such a DNA coding such and a method for producing such.
• the invention further relates to the use of the DNA and the protein and antibodies directed against the protein.
• GABA A receptors These are membrane proteins that bind the neurotransmitter y-aminobutyric acid (GABA). This binding triggers a synaptic inhibition, whereby chloride channels are opened.
• GABA A receptors consist of subunits, in particular those of the classes alpha, beta, gamma, delta, epsilon and rho.
• the object of the present invention is therefore to provide a means with which the signal transmission in the brain can be examined and, if necessary, influenced.
• the present invention thus relates to a GABA A receptor subunit epsilon-related protein, the protein comprising the amino acid sequence of FIG. 1 or an amino acid sequence different therefrom by one or more amino acids.
• the present invention is based on the knowledge of the applicant that in animals, particularly mammals, very particularly humans, a protein exists which has homologies to a GABA A receptor subunit epsilon, where appropriate a GABA A receptor subunit epsiion activity but differs from a known GABA A receptor subunit epsilon at the DNA level by hybridization under normal conditions.
• Such a protein has the amino acid sequence of FIG. 1 or an amino acid sequence different therefrom by one or more amino acids.
• the latter amino acid sequence is represented, for example, by that of FIG. 2.
• GVP GABA A receptor subunit epsilon-related protein
• Another object of the present invention is a nucleic acid coding for a (GVP).
• GVP nucleic acid coding for a
• This can be an RNA or a DNA.
• the latter can e.g. be a genomic DNA or a cDNA.
• a DNA is preferred which comprises the following:
• hybridizing DNA indicates a DNA that is commonly used
• the DNA of FIG. 3 was deposited with the DSM (German Collection of Microorganisms and Cell Cultures) as Qc 1 1 C8 under DSM 1 1 1 96 on October 2, 996.
• the DNA of FIGS. 1 and 2 is further preferred.
• the DNA of FIG. 2 differs from that of FIG. 1 in that 96 bp are missing between positions 378-474.
• the (GVPs) encoded by both DNAs differ accordingly, ie (GVP) of FIG. 2 is 32 amino acids shorter than that of FIG. 1.
• a DNA according to the invention is described below in the form of a cDNA. This is an example of every DNA covered by the present invention.
• This library is made up of a DNA fragment, e.g. B. 58g2B1 8, which is isolated from the cosmid clone Qc1 1 C8 by means of direct cDNA selection (cf. Korn, B. et al., Hum.Mol.Genet.4, (1 992), 235-242) .
• the cosmid clone Qc1 1 C8 becomes an Xq28 specific
• a cDNA according to the invention can be present in a vector or expression vector.
• examples of such are known to the person skilled in the art.
• these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b and pQE-8, the latter being preferred.
• yeast e.g. to call pY1 00 and Ycpad l
• animal cells e.g. pKCR, pEFBOS, cDM8 and pCEV4 must be specified.
• the baculovirus expression vector pAcSGHisNT-A is particularly suitable for expression in insect cells.
• suitable cells in order to express a cDNA according to the invention which is present in an expression vector.
• suitable cells include the E. coli strains HB1 01, DH 1, x1 776, JM 101, JM 109, BL21 and
• yeast strain Saccharomyces cerevisiae and the animal cells Ltk " , 3T3, FM3A, CHO, COS, Vero and HeLa as well as the insect cells sf9.
• a cDNA according to the invention has to be inserted into an expression vector. He is also aware that this DNA can be inserted in connection with a DNA coding for another protein or peptide, so that the cDNA according to the invention can be expressed in the form of a fusion protein.
• Another object of the present invention is an antibody directed against an above protein or fusion protein.
• Such an antibody can be produced by conventional methods. It can be polyclonal or monoclonal. For its production, it is expedient to immunize animals, in particular rabbits or chickens for a polyclonal and mice for a monoclonal antibody, with an above (fusion) protein or fragments thereof. Further “boosters” of the animals can be carried out using the same (fusion) protein or fragments thereof. The polyclonal antibody can then be obtained from the serum or egg yolk of the animals. For the monoclonal antibody, animal spleen cells are fused with myeloma cells.
• the present invention makes it possible to investigate signal transmission in the brain.
• GVP antibody according to the invention
• an antibody according to the invention (GVP) can be detected in the brain cells of people.
• a relationship between (GVP) and the transmission of signals can be established.
• an autoantibody directed against this protein can be detected with an inventive (GVP).
• Both detections can be carried out by conventional methods, in particular a Western blot, an ELISA, an immunoprecipitation or by Immunofluorescence.
• the expression of the gene coding for (GVP) can be detected with a nucleic acid according to the invention, in particular a DNA and primers derived therefrom. This detection can be done in the usual way, especially in a Southern blot.
• the present invention is suitable for regulatingly intervening in the transmission of signals in the brain of persons.
• GVP antibody according to the invention
• this can be achieved by means of a nucleic acid according to the invention, in particular DNA.
• the nucleic acid e.g. as the basis for the creation of
• Anti-sense oligonucleotides used to inhibit expression of the gene coding for (GVP).
• the present invention is furthermore suitable for finding substances which bind specifically to (GVP) and influence it.
• GVP GABA A receptor units
• Such an expression can also take place in Xenopus oocytes.
• benzodiazepines, barbiturates, beta-carbolines and neurosteroids are conceivable as substances that could have an influence on (GVP).
• the influence of substances can be examined by conventional methods, in particular pharmacological and electrophysiological methods. For example, reference is made to radioligand binding tests and the use of the patch clamp technique on whole cells (cf. Pritchett et al., Nature 338, (1 989), 582-585).
• (GVP) can also be present in a GABA A receptor. Such is also the subject of the present invention.
• the present invention thus makes a great contribution to the understanding of the Signal transmission in the brain and a possible regulatory intervention.
• FIG. 1 shows the base sequence of a cDNA according to the invention and the amino acid sequence derived therefrom of a (GVP) according to the invention
• FIG. 3 shows the base sequence of a genomic DNA coding for an inventive (GVP).
• GVP inventive
• Example 1 Production and cleaning of a (GVP) according to the invention
• the DNA of FIG. 1 was used as a template for producing a (GVP) according to the invention.
• a PCR procedure was carried out.
• the DNA of FIG. 1 the following was used as the primer pair:
• the amplified DNA was in each case cleaved with BamHI and inserted into the expression vector pQE-8 (Diagen) cleaved with BamHI.
• the expression plasmid pQ / GVP-1 was obtained.
• pQ / GVP-G-1 was used to transform E.coli SG 1 3009 (see Gottesman, S. et al., J. Bacteriol. 1 48, (1 981), 265-273).
• the bacteria were in an LB medium with 100 ⁇ g / ml ampicillin and 25 ⁇ g / ml kanamycin cultivated and induced for 4 h with 60 ⁇ M isopropyl-ß-D-thiogalactopyranoside (IPTG).
• IPTG isopropyl-ß-D-thiogalactopyranoside
• the bacteria were lysed by adding 6 M guanidine hydrochloride, and then chromatography (Ni-NTA resin) was carried out with the lysate in the presence of 8 M urea in accordance with the manufacturer's (Diagen) instructions for the chromatography material.
• the bound fusion protein was eluted in a pH 3.5 buffer.
• the fusion protein was subjected to 1 8% SDS-polyacrylamide gel electrophoresis and stained with Coomassie blue (cf. Thomas, JO and Kornberg, RD, J. Mol. Biol. 1 49 (1 975), 709-733) .
• Example 2 Production and detection of an antibody according to the invention
• a fusion protein according to the invention from Example 1 was subjected to 1 8% SDS-polyacrylamide gel electrophoresis. After staining the gel with 4 M sodium acetate, an approximately 54 kD band was cut out of the gel and incubated in phosphate-buffered saline. Gel pieces were sedimented before the protein concentration of the supernatant was determined by SDS polyacrylamide gel electrophoresis, which was followed by a Coomassie blue staining. Animals were immunized with the gel-purified fusion protein as follows:
• the rabbit's serum was tested in the immunoblot.
• nitrocellulose filter Subjected to gel electrophoresis and transferred to a nitrocellulose filter (cf. Khyse-Andersen, J., J. Biochem. Biophys. Meth. 10, (1 984), 203-209). Western blot analysis was performed as in Bock, C.-T. et al., Virus Genes 8, (1 994), 21 5-229. For this purpose, the nitrocellulose filter was incubated for one hour at 37 ° C. with a first antibody. This antibody was rabbit serum (1: 10000 in PBS). After several washes with PBS, the nitrocellulose filter was incubated with a second antibody.
• This antibody was a goat anti-rabbit IgG (Dianova) monoclonal monoclonal antibody coupled to alkaline phosphatase (1: 5000) in PBS. After 30 minutes of incubation at 37 ° C, several washing steps with PBS followed and then the alkaline phosphatase detection reaction with developer solution (36 ⁇ M 5 'bromo-4-chloro-3-indolylphosphate, 400 ⁇ M nitroblue tetrazolium, 100mM Tris-HCl, pH 9.5 , 100 mM NaCl, 5 M MgCl 2 ) at room temperature until bands were visible.
• developer solution 36 ⁇ M 5 'bromo-4-chloro-3-indolylphosphate, 400 ⁇ M nitroblue tetrazolium, 100mM Tris-HCl, pH 9.5 , 100 mM NaCl, 5 M MgCl 2
• Antibodies were extracted from egg yolk and tested in a Western blot. Polyclonal antibodies according to the invention have been detected.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Neurosurgery (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Zoology (AREA)
• Toxicology (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Cell Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7810044

Family Applications (1)

Country Status (4)

Families Citing this family (1)

Family Cites Families (1)

• 1996
  • 1996-10-25 DE DE19644501A patent/DE19644501A1/de not_active Withdrawn
• 1997
  • 1997-10-24 JP JP51989998A patent/JP2001503618A/ja active Pending
  • 1997-10-24 EP EP97946742A patent/EP0938558A2/de not_active Withdrawn
  • 1997-10-24 WO PCT/DE1997/002499 patent/WO1998018919A2/de not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events